Navigation Links
Evalve(R) Completes $60 Million Series D Financing
Date:11/27/2007

ing as an investor in this round of funding through his new fund, Emergent Medical Ventures.

"We welcome Ryan to the board where his expertise and experience will be an important resource for Evalve as we move forward toward commercialization," said Ms. Powell. "At the same time, we are pleased that Dr. Fogarty will continue to be involved with the company. His contributions have been a strong factor in our success throughout our history and in the development of the MitraClip device."

EVEREST Study Continues Enrollment

The EVEREST II study continues at more than 35 centers in North America with more than 300 patients enrolled and more than 300 MitraClip devices implanted to date. Investigators are currently enrolling patients in both arms of the EVEREST II study -- a randomized, controlled arm and a high risk registry arm -- with the goal of completing enrollment by the end of 2008.
Enrollment in the study is open to a range of patients:

-- Patients with either degenerative or functional MR.

-- Patients who are good surgical candidates and are open to the option

of a less invasive approach.

-- High risk patients who are not good candidates for surgery will be

enrolled in the EVEREST High Risk Registry until enrollment is

complete in this arm by the end of 2007.

The EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) randomized study is evaluating the safety and efficacy of the MitraClip device compared to surgical mitral valve repair or replacement. This prospective, randomized, multi-center study will enroll 279 patients at up to 42 sites in the United States and Canada. Patients are randomized 2:1 to receive the MitraClip device. Patients who are interested in participation in the study can call 1-877-MY-MR-FIX (1-877-696-7349). More information about the EVEREST II trial is available at http://www.mitralregur
'/>"/>

SOURCE Evalve, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Juvent Sports ... growing list of major sports figures who are finding joint pain relief after using ... former #1 men’s tennis player in the world said, “For the first time in ...
(Date:8/31/2015)... ... August 31, 2015 , ... According to book reviewer ... Charge of Your Life with Cancer is an excellent resource for everyone since ... Cancer Solution to be helpful in explaining what cancer is in a easy to ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Intellitec Solutions announced ... by bringing on board their 8th new staff member in 2015. With the potential ... the firm. Intellitec Solutions supports Microsoft Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in ... test marketing a doctor note service to be made available to all patients ... for each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... ... 31, 2015 , ... Avid collector Andrew Hawley from Vintage Rock Posters announces ... This hand colored artwork is one of the most coveted Doors concert posters. The ... the doors played the Shrine, the band was one of the biggest bands ...
Breaking Medicine News(10 mins):Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... activity, appears to be able to detect awareness in some ... new Canadian study finds. Functional MRI (fMRI) is also ... but the high cost and limited availability of these devices ...
... HealthDay Reporter , THURSDAY, Nov. 10 (HealthDay News) -- People ... restless legs syndrome, but many people with Parkinson,s do report ... new Norwegian study. People with restless legs ... legs. This typically occurs at night during rest, and the ...
... can lead to major health issues, including significant cognitive ... Departments of Neurology, Neurosurgery and Psychiatry at NYU Langone ... Nov. 10, 2011 issue of the New England ... sudden, unexpected death in epilepsy (SUDEP) and offers guidance ...
... This press release is available in German . ... mirror-inverted manner. They differ from each other like a left ... is referred to as chirality is of particular relevance to ... dioxide or methane are not chiral, many biologically relevant molecules, ...
... disease that many parents, even some doctors, mistake for ... diagnosed or treated in time, it can lead to ... genetic studies, scientists have been unable to pinpoint the ... an international team of scientists organized by Jane C. ...
... 2011)A new national initiative, IPAL-EM (Improving Palliative Care in ... palliative care when seriously ill patients are admitted to ... the role of the palliative care in emergency medicine, ... challenge of cultures and mindset. Supported by the ...
Cached Medicine News:Health News:Brain Study Suggests Some Vegetative Patients Are Aware 2Health News:Brain Study Suggests Some Vegetative Patients Are Aware 3Health News:Classic Restless Legs Syndrome Not Linked to Parkinson's 2Health News:NYU Langone expert calls for awareness, research of sudden death in patients with epilepsy 2Health News:Flexible rack systems sort molecules 2Health News:Kawasaki disease linked to wind currents 2Health News:Kawasaki disease linked to wind currents 3Health News:IPAL-EM launches to improve palliative care in emergency medicine 2
(Date:8/27/2015)... Aug. 27, 2015  The Academy of Managed ... Drug Administration,s (FDA,s) draft guidance and proposed rule ... biosimilars, to bear a nonproprietary name with an ... seeking a decision from the FDA on the ... care stakeholders urging the agency to use the ...
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate for ... proven, simple and effective palliative treatment of advanced prostate ... is the first and only six-month intramuscular (IM) GnRH ...
... the bio-pharmaceutical industry, new product commercialization efforts have taken on increased importance. It,s against this backdrop that new product planning ... , ... , ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 2Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 3Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 4
... 20 fume containment system work station ... swing-down front panel hinges from top ... opening. The sides and front ... is impervious to most chemicals. ...
... The STREP A OIA MAX test delivers ... Group A Strep with a simple, easy-to-use ... This combination of performance, speed, and ease-of-use ... while reducing overall costs for diagnosing and ...
... The FLU OIA A/B test combines performance equivalence ... of Influenza A or B with a simple, ... minutes. The test has all the same procedural ... test will enable you decrease costs for unnecessary ...
... The Acceava Mononucleosis test provides ... Mononucleosis with a simple procedure that ... Side-by-side evaluations with competitive products will ... These attributes enable you to deliver ...
Medicine Products: